Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy
Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype characterized by aggressive clinical behavior and poor prognosis. The immune landscape associated with TNBC often reveals high immunogenicity. Therefore, immunotherapy, which has demonstrated its efficacy in different canc...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/1/e009548.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841536291924082688 |
|---|---|
| author | Valérie Laurent-Matha Pascal Roger Séverine Guiu Thierry Chardès Emmanuelle Liaudet-Coopman Pénélope Desroys du Roure Timothée David Aude Mallavialle |
| author_facet | Valérie Laurent-Matha Pascal Roger Séverine Guiu Thierry Chardès Emmanuelle Liaudet-Coopman Pénélope Desroys du Roure Timothée David Aude Mallavialle |
| author_sort | Valérie Laurent-Matha |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype characterized by aggressive clinical behavior and poor prognosis. The immune landscape associated with TNBC often reveals high immunogenicity. Therefore, immunotherapy, which has demonstrated its efficacy in different cancer types, could be a promising strategy for TNBC, given the limited therapeutic options currently available besides conventional chemotherapy. The aspartic protease cathepsin D (cath-D) is a tumor cell-associated extracellular protein with protumor activity, a marker of poor prognosis, and a target for antibody-based therapy in TNBC. This commentary provides a synopsis/narrative summary of the development of anti-cath-D antibodies in different formats, their key roles in restoring the antitumor immunity, particularly via activation of tumor-infiltrating natural killer cells, and their dual antitumor effects on cancer cells and stromal cancer-associated fibroblasts, suggesting their interest for clinical use in the light of the current clinical knowledge on TNBC. |
| format | Article |
| id | doaj-art-df7edb8a44c84e268fe124ad32df642a |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-df7edb8a44c84e268fe124ad32df642a2025-01-14T23:10:11ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-01-0113110.1136/jitc-2024-009548Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapyValérie Laurent-Matha0Pascal Roger1Séverine Guiu2Thierry Chardès3Emmanuelle Liaudet-Coopman4Pénélope Desroys du Roure5Timothée David6Aude Mallavialle7IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, FranceAff1 grid.411439.a0000 0001 2150 9058IRCM, INSERM, U1194 Univ Montpellier, ICM 208, rue des Apothicaires F-34298 Montpellier, Cedex 5 FranceAff1 grid.411439.a0000 0001 2150 9058IRCM, INSERM, U1194 Univ Montpellier, ICM 208, rue des Apothicaires F-34298 Montpellier, Cedex 5 FranceAff1 grid.411439.a0000 0001 2150 9058IRCM, INSERM, U1194 Univ Montpellier, ICM 208, rue des Apothicaires F-34298 Montpellier, Cedex 5 FranceAff1 grid.411439.a0000 0001 2150 9058IRCM, INSERM, U1194 Univ Montpellier, ICM 208, rue des Apothicaires F-34298 Montpellier, Cedex 5 FranceIRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, FranceIRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, FranceIRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, FranceTriple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype characterized by aggressive clinical behavior and poor prognosis. The immune landscape associated with TNBC often reveals high immunogenicity. Therefore, immunotherapy, which has demonstrated its efficacy in different cancer types, could be a promising strategy for TNBC, given the limited therapeutic options currently available besides conventional chemotherapy. The aspartic protease cathepsin D (cath-D) is a tumor cell-associated extracellular protein with protumor activity, a marker of poor prognosis, and a target for antibody-based therapy in TNBC. This commentary provides a synopsis/narrative summary of the development of anti-cath-D antibodies in different formats, their key roles in restoring the antitumor immunity, particularly via activation of tumor-infiltrating natural killer cells, and their dual antitumor effects on cancer cells and stromal cancer-associated fibroblasts, suggesting their interest for clinical use in the light of the current clinical knowledge on TNBC.https://jitc.bmj.com/content/13/1/e009548.full |
| spellingShingle | Valérie Laurent-Matha Pascal Roger Séverine Guiu Thierry Chardès Emmanuelle Liaudet-Coopman Pénélope Desroys du Roure Timothée David Aude Mallavialle Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy Journal for ImmunoTherapy of Cancer |
| title | Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy |
| title_full | Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy |
| title_fullStr | Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy |
| title_full_unstemmed | Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy |
| title_short | Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy |
| title_sort | antibodies against the multifaceted cathepsin d protein open new avenues for tnbc immunotherapy |
| url | https://jitc.bmj.com/content/13/1/e009548.full |
| work_keys_str_mv | AT valerielaurentmatha antibodiesagainstthemultifacetedcathepsindproteinopennewavenuesfortnbcimmunotherapy AT pascalroger antibodiesagainstthemultifacetedcathepsindproteinopennewavenuesfortnbcimmunotherapy AT severineguiu antibodiesagainstthemultifacetedcathepsindproteinopennewavenuesfortnbcimmunotherapy AT thierrychardes antibodiesagainstthemultifacetedcathepsindproteinopennewavenuesfortnbcimmunotherapy AT emmanuelleliaudetcoopman antibodiesagainstthemultifacetedcathepsindproteinopennewavenuesfortnbcimmunotherapy AT penelopedesroysduroure antibodiesagainstthemultifacetedcathepsindproteinopennewavenuesfortnbcimmunotherapy AT timotheedavid antibodiesagainstthemultifacetedcathepsindproteinopennewavenuesfortnbcimmunotherapy AT audemallavialle antibodiesagainstthemultifacetedcathepsindproteinopennewavenuesfortnbcimmunotherapy |